FDA approves first short-acting “follow-on” insulin

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway

  • Sanofi’s version of insulin lispro injection (Admelog) may be less costly for patients.

Key facts

  • Approved as a short-acting insulin to improve blood glucose control in adults with type 1 or type 2 diabetes and children with type 1 diabetes down to age 3 years.
  • It is app...